The first day of the haematology conference sees first-in-human data from two antibody-drug conjugates belonging to Immunogen, a company eager to draw a line under a…
Celgene’s deal-making skills have come under the microscope of late, but the group finally seems to have struck a good bargain with Acceleron and luspatercept.
December will be a big month for Achillion's complement inhibitor and Aquestive's ALS hopes.
The final month of 2018 will see FDA verdicts on Roche’s bid to play in the first-line lung cancer space, and what Jazz hopes will be its next big narcolepsy product.
Masterkey-265 will test the sector’s renewed interest in oncolytic viruses as a way of turning “cold" tumours "hot”.
A two-for-one holiday sale is coming for Hetlioz and tradipitant, and Evofem hopes to confirm its contraceptive gel's effectiveness.
The private UK group could steal the thunder of rivals like Spark, Uniqure and Biomarin.
Swedish Orphan Biovitrum made waves yesterday by getting its rare disease asset emapalumab into the Ash late-breakers – and bagging approval soon afterwards.
The Ash meeting starts on December 1. Here are some haematological cancer presentations that investors will be focusing on, as biotech risks ending 2018 in poor shape.